American Heart Journal
Volume 154, Issue 1 , Pages 39-45 , July 2007

Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: Design and rationale for the MULTI-STRATEGY trial

  • Marco Valgimigli, MD, PhD

      Affiliations

    • Cardiology, University of Ferrara, Ferrara, Italy
    • Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago, Brescia, Italy
    • Corresponding Author InformationReprint requests: Marco Valgimigli, MD, PhD, Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S. Anna Hospital, C.rso Giovecca 203, 44100 Ferrara, Italy.
    • ,
  • Leonardo Bolognese, MD

      Affiliations

    • Cardiovascular Departments of San Donato Hospital, Arezzo, Italy
    • ,
  • Maurizio Anselmi, MD

      Affiliations

    • Department of Biomedical and Surgical Sciences, Section of Cardiology, University of Verona, Verona, Italy
    • ,
  • Gianluca Campo, MD

      Affiliations

    • Cardiology, University of Ferrara, Ferrara, Italy
    • ,
  • Alfredo E. Rodriguez, MD, PhD

      Affiliations

    • Otamendi Hospital, Buenos Aires, Argentina
    • ,
  • Nicoletta de Cesare, MD

      Affiliations

    • Policlinico S. Marco, Zingonia, Bergamo, Italy
    • ,
  • David J. Cohen, MD, MSc

      Affiliations

    • Saint Luke's Mid America Heart Institute, Kansas City, MO
    • ,
  • Imad Sheiban, MD

      Affiliations

    • Interventional Cardiology, University of Turin, San Giovanni Battista Hospital, Turin, Italy
    • ,
  • Salvatore Colangelo, MD

      Affiliations

    • Cardiovascular Intervention Laboratory San Giovanni Bosco Hospital, Turin, Italy
    • ,
  • Giampaolo Pasquetto, MD

      Affiliations

    • Department of Cardiology, Civic Hospital, Mirano, Venice, Italy
    • ,
  • Martial Hamon, MD

      Affiliations

    • Department at the University Hospital of Caen, Normandy, France
    • ,
  • Pascal Vranckx, MD

      Affiliations

    • Virga Jesseziekenhuis, Hasselt, Belgium
    • ,
  • Maurizio Ferrario, MD

      Affiliations

    • Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S. Matteo, Pavia, Italy
    • ,
  • Francesco Prati, MD, PhD

      Affiliations

    • Department of Cardiovascular Medicine, Catholic University of the Sacred heart, Rome, Italy
    • ,
  • Pierfrancesco Agostoni, MD

      Affiliations

    • Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium
    • ,
  • Patrizia Malagutti, MD

      Affiliations

    • Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago, Brescia, Italy
    • ,
  • Chiara Arcozzi, MD

      Affiliations

    • Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago, Brescia, Italy
    • ,
  • Giovanni Parrinello, PhD

      Affiliations

    • Medical Statistics Unit, University of Brescia, Italy
    • ,
  • Corrado Vassanelli, MD

      Affiliations

    • Department of Biomedical and Surgical Sciences, Section of Cardiology, University of Verona, Verona, Italy
    • ,
  • Roberto Ferrari, MD, PhD

      Affiliations

    • Cardiology, University of Ferrara, Ferrara, Italy
    • Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago, Brescia, Italy
    • ,
  • Gianfranco Percoco, MD

      Affiliations

    • Cardiology, University of Ferrara, Ferrara, Italy

Received 16 December 2006 ,Accepted 15 March 2007.

References 

  1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82–e292
  2. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1886–1889
  3. Van de Werf F. Drug-eluting stents in acute myocardial infarction. N Engl J Med. 2006;355:1169–1170
  4. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001;88:297–301
  5. Nordmann AJ, Bucher H, Hengstler P, et al. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev. 2005;CD005313
  6. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293:2109–2117
  7. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093–1104
  8. Menichelli M. Randomised trial of sirolimus eluting stent vs. bare metal stent in acute myocardial infarction (SESAMI). In: Presented at 2006 Euro-PCR, 16th May 2006, Paris. 2006;
  9. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105–1113
  10. Valgimigli M, Percoco G, Bolognese L. Drug-eluting stents in primary PCI. N Engl J Med. 2006;355:2484;[author reply 2484-6]
  11. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759–1765
  12. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–1894
  13. Schneider DJ, Herrmann HC, Lakkis N, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol. 2003;91:334–336
  14. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol. 2004;44:14–19
  15. Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol. 2004;94:35–39
  16. Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol. 2006;47:522–528
  17. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803–2809
  18. Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152–1160
  19. van't Hof AW, Liem A, de Boer MJ, et al. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 1997;350:615–619
  20. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation. 2004;110:e506–e510
  21. De Luca G, van't Hof AW, de Boer MJ, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J. 2004;25:1009–1013
  22. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879–1885
  23. Godicke J, Flather M, Noc M, et al. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J. 2005;150:1015
  24. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol. 2006;48:2178–2185
  25. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293:1063–1072
  26. McAlister FA, Straus SE, Sackett DL, et al. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003;289:2545–2553

 The conduct of this study was partially supported by Merck Company (Whitehouse Station, NJ).

PII: S0002-8703(07)00245-1

doi: 10.1016/j.ahj.2007.03.023

American Heart Journal
Volume 154, Issue 1 , Pages 39-45 , July 2007

Article Tools

* Image Usage & Resolution